Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
DXM Abuse Prevention Act of 2019 This bill addresses the sale and distribution of dextromethorphan (DXM). Specifically, the bill requires a retailer that sells certain drugs containing DXM to have a verification system that is intended to ensure that no one under 18 years of age purchases such drugs from the retailer. The bill also establishes restrictions on (1)the sale of over-the-counter drugs containing DXM, and (2)the distribution of bulk DXM.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2020 · fourth_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $1,370,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2020 · fourth_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials - Issues related to 340B - S.4613, The Contact Lens Rule Modernization Act, regarding all provisions - H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications -H.R.133 - Consolidated Appropriations Act, 2021, including legislation regarding average sales price (ASP) reporting requirements for certain hyaluronic acid (HA) products that are classified as devices, but reimbursed as drugs under Medicare Part B
Client expense: $1,450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · fourth_quarter · Alcohol and Drug Abuse
H.R.863 - DXM Abuse Prevention Act of 2019 - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. H.R.2020/S.989 - STEER Act -- Tableting and Encapsulating Machine Regulation Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 H.R.3171 - Safe Disposal of Opioids Act of 2019 S.2584 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020 S.2102 - Turn the Tide Act H.R.4510 - Criminalizing Abused Substance Templates Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020 S.4612 - Methamphetamine Response Act of 2020 H.R.8210 - Methamphetamine Response Act of 2020
Client expense: $146,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
2020 · third_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to the Rare Pediatric Disease Priority Review Voucher Program. Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HSA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Client expense: $1,430,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2020 · third_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials - Issues related to 340B - S.4613, The Contact Lens Rule Modernization Act, regarding all provisions - H.R.3107, "Improving Seniors Timely Access to Care Act of 2019, regarding all provisions - Executive Order 13948: Lowering Drug Prices by Putting America First - Executive Order 13939: Lowering Prices for Patients by Eliminating Kickbacks to Middlemen - Executive Order 13938: Increasing Drug Importation To Lower Prices for American Patients - Executive Order 13937: Access to Affordable Life-Saving Medications
Client expense: $860,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2020 · third_quarter · Alcohol and Drug Abuse
H.R.863 - DXM Abuse Prevention Act of 2019 - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. H.R.2020/S.989 - STEER Act -- Tableting and Encapsulating Machine Regulation Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 H.R.3171 - Safe Disposal of Opioids Act of 2019 S.2584 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020 S.2102 - Turn the Tide Act H.R.4510 - Criminalizing Abused Substance Templates Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020
Client expense: $140,000 · Firm income: Not reported
2020 · second_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. Monitor legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor legislative and administrative action related to implementation of P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HASA/FSA provisions. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
2020 · second_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions - Issues related to social determinants of health - H.R. 5076/S. 1872, "Protecting Seniors Through Immunization", regarding all provisions - H.R.6062, "To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes", regarding all provisions. - H.R.6952, "To direct the President to appoint a Medical Supplies Response Coordinator to coordinate the efforts of the Federal Government regarding the supply and distribution of certain supplies and equipment relating to COVID-19", regarding all provisions - S.3942, "Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act", regarding all provisions - S.3945, "Bring Entrepreneurial Advancements To Consumers Here In North America Act", regarding all provisions - S.3780, "HOME Act", regarding all provisions - S.3781, "PART Act", regarding all provisions - Issues related to diversity in clinical trials
2020 · second_quarter · Alcohol and Drug Abuse
H.R.863 - DXM Abuse Prevention Act of 2019 - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. H.R.2020/S.989 - STEER Act -- Tableting and Encapsulating Machine Regulation Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 H.R.3171 - Safe Disposal of Opioids Act of 2019 S.2584 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020 S.2102 - Turn the Tide Act H.R.4510 - Criminalizing Abused Substance Templates Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020
Client expense: $128,000 · Firm income: Not reported
2020 · first_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Client expense: $1,960,000 · Firm income: Not reported
2020 · first_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. Monitor legislative and administrative action related to COVID-19, including drug supply chain issues. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including monograph reform and HAS/FSA provisions. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Client expense: $1,890,000 · Firm income: Not reported
2020 · first_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions - H.R. 748/ S. 3458, "'Coronavirus Aid, Relief, and. Economic Security Act'', regarding all provisions - H.R. 6074, "Coronavirus Preparedness and Response Supplemental Appropriations Act", regarding all provisions - H.R. 6201, "Families First Coronavirus Response Act", regarding all provisions - H.R. 3975, the Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 5663, the Safeguarding Therapeutics Act, regarding all provisions - Issues related to counterfeit health care goods - S. 3468, Preventing Essential Medical Device Shortages Act of 2020 - Issues related to counterfeit medical devices and combination products and authority to destroy counterfeit medical products - Issues related to reporting medical device shortages - Issues related to pandemic response - S. 2740, "Over the Counter Monograph Safety, Innovation, and Reform Act of 2019", regarding all provisions - H.R. 5279, "Cosmetic Safety Enhancement Act", regarding all provisions - H.R. 4296, "Safe Cosmetics and Personal Care Products Act of 2019", regarding all provisions
2020 · first_quarter · Alcohol and Drug Abuse
H.R.863 - DXM Abuse Prevention Act of 2019 - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. H.R.2020/S.989 - STEER Act -- Tableting and Encapsulating Machine Regulation Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 H.R.3171 - Safe Disposal of Opioids Act of 2019 S.2584 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020 S.2102 - Turn the Tide Act H.R.4510 - Criminalizing Abused Substance Templates Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020
Client expense: $165,000 · Firm income: Not reported
2019 · fourth_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to repealing the medical device tax. Monitor legislative and administrative action related to sunscreen issues. Monitor legislative and administrative action related to P.L. 113-195, The Sunscreen Innovation Act. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
2019 · fourth_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease - H.R. 3, "Elijah E. Cummings Lower Drug Costs Now Act", regarding all provisions - Issues related to drug importation - S. 2543, "Prescription Drug Pricing Reduction Act of 2019", regarding all provisions - H.R. 19, "Lower Costs, More Cures Act of 2019", regarding all provisions
Client expense: $1,350,000 · Firm income: Not reported
2019 · fourth_quarter · Alcohol and Drug Abuse
H.R.863 - DXM Abuse Prevention Act of 2019 - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. H.R.2020/S.989 - STEER Act -- Tableting and Encapsulating Machine Regulation Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 H.R.3171 - Safe Disposal of Opioids Act of 2019 S.2584 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020 S.2102 - Turn the Tide Act H.R.4510 - Criminalizing Abused Substance Templates Act of 2019 H.R.1865 - Further Consolidated Appropriations Act, 2020
Client expense: $177,500 · Firm income: Not reported
2019 · third_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to repealing the medical device tax. Monitor legislative and administrative action related to sunscreen issues. Monitor legislative and administrative action related to P.L. 113-195, The Sunscreen Innovation Act. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019.
2019 · third_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the regulation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to medical product communications - Issues related to medical product review - Issues related to ingredient safety - Issues related to drug pricing reform - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease
Client expense: $810,000 · Firm income: Not reported
2019 · third_quarter · Alcohol and Drug Abuse
H.R.863 - DXM Abuse Prevention Act of 2019 - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. H.R.2020/S.989 - STEER Act -- Tableting and Encapsulating Machine Regulation Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 H.R.3171 - Safe Disposal of Opioids Act of 2019 S.2584 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2020 S.2102 - Turn the Tide Act H.R.4510 - Criminalizing Abused Substance Templates Act of 2019
Client expense: $166,000 · Firm income: Not reported
2019 · second_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to repealing the medical device tax. Monitor legislative and administrative action related to sunscreen issues. Monitor legislative and administrative action related to P.L. 113-195, The Sunscreen Innovation Act. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019.
Client expense: $2,610,000 · Firm income: Not reported
2019 · second_quarter · Alcohol and Drug Abuse
H.R.863 - DXM Abuse Prevention Act of 2019 - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. Tableting and Encapsulating Machine Regulation Act, no bill number. Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs. H.R.3055 - Commerce, Justice, Science, Agriculture, Rural Development, Food and Drug Administration, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2020 H.R.3171 - Safe Disposal of Opioids Act of 2019
Client expense: $173,000 · Firm income: Not reported
2019 · second_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - Issues related to the reputation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to the medical device tax repeal - Issues related to medical product communications - Issues related to medical product review - Issues related to talc safety - Issues related to drug pricing reform - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease
Client expense: $2,150,000 · Firm income: Not reported
2019 · second_quarter · Alcohol and Drug Abuse
Issues related to the sale of medicines that contain dextromethorphan, including H. R. 863, the DXM Abuse Prevention Act of 2019.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · first_quarter · Health Issues
Monitor legislative and administrative action related to health care policy. Monitor legislative and administrative action related to drug importation, drug shortages, authorized genetics, and prescription drug advertising. Monitor legislative and administrative action related to womens health issues. Monitor legislative and administrative action related to over-the-counter consumer care products. Monitor legislative and administrative action related to dietary supplements. Monitor legislative and administrative action related to servicing of medical device equipment. Monitor legislative and administrative action related to FDA monograph reform and user fees. Monitor legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor legislative and administrative action related to repealing the medical device tax. Monitor legislative and administrative action related to sunscreen issues. Monitor legislative and administrative action related to P.L. 113-195, The Sunscreen Innovation Act. Monitor legislative and administrative action related to cosmetics reform legislation. Monitor legislative and administrative action related to drug take back and pseudoephedrine regulation. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019. H.R. 863, DXM Abuse Prevention Act of 2019. H.R. 965, CREATES Act of 2019. H.R. 985, FAST Generics Act of 2019. H.R. 1344, Competitive DRUGS Act of 2019. H.R. 1503, Orange Book Transparency Act of 2019. H.R. 1520, Purple Book Continuity Act of 2019. S. 340, CREATES Act of 2019.
Client expense: $2,420,000 · Firm income: Not reported
2019 · first_quarter · Health Issues
- H.R. 863 - DXM Abuse Prevention Act of 2019, regarding all provisions - S. 726 - Personal Care Products Safety Act, regarding all provisions - H.R. 269 - Pandemic and All-Hazards Preparedness & Advancing Innovation Act of 2019, regarding all provisions - Issues related to the reputation of over-the-counter drugs - Issues related to cosmetic regulatory reform - Issues related to cosmetic animal testing - Issues related to biosimilars - Issues related to maternal mortality - Issues related to contact lens safety - Issues related to the medical device tax repeal - Issues related to medical product communications - Issues related to medical product review - Issues related to talc safety - Issues related to drug pricing reform - Issues related to diversity in clinical trials - Issues related to health care pricing transparency - Issues related to peripheral artery disease
Client expense: $1,440,000 · Firm income: Not reported
2019 · first_quarter · Alcohol and Drug Abuse
Issues related to the sale of medicines that contain dextromethorphan, including H. R. 863, the DXM Abuse Prevention Act of 2019.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2019 · first_quarter · Alcohol and Drug Abuse
H.R.863 - DXM Abuse Prevention Act of 2019 - legislation that would ban the sale of over-the-counter cough and cold medications containing the active ingredient dextromethorphan (DXM) to minors under the age of 18. Additionally, would ban the sale of bulk, unfinished DXM to entities not registered with the U.S. Food and Drug Administration; all sections. Tableting and Encapsulating Machine Regulation Act, no bill number. Gives the Drug Enforcement Agency additional authority to regulate tableting and encapsulating manufacturing machines. FDA Packaging and Disposal, no bill number. Directs FDA to work with manufacturers to establish programs for efficient return or destruction of unused Schedule II drugs, with an emphasis on opioids. These methods could include mail-back pouches to secure facilities for incineration, or methods to immediately inactivate/render unattractive unused drugs.
Client expense: $159,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
Client expense: $1,750,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
Client expense: $1,760,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of, Vice President of the U.S.
Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Government targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Client expense: $1,480,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, Treasury, Dept of
Client expense: $1,910,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Client expense: $2,110,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, Small Business Administration (SBA), State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Government targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of